New clinical findings target therapy-proof cancers by locating the exact molecular process keeping each tumour alive through treatment, then blocking that process with an agent designed for it. Sequencing programs associated with Lisa Porter London identify genetic shifts as they occur, allowing intervention before full resistance develops and the tumour rebuilds around the change.
Genome sequencing exposes rewiring
Sequencing treatment-refractory tumour tissue directly shows which signalling pathway the cancer cell switched to after the targeted drug blocked its original route. That switch is not random. Refractory tumour data across multiple cancer types show resistance consistently routes through one of a small number of alternative circuits, and identifying which circuit is active tells the oncologist which agent blocks it.
Refractory colorectal tumour sequencing reveals concurrent alterations in DNA damage repair genes and apoptosis regulators together. That specific combination disconnects the cell from two death signals at once, which is why single-agent salvage fails in these cases. Sequencing both alterations at relapse directly identifies the two pathway agents needed in combination, because one alone leaves the second signal open as a functional escape route that the cell immediately uses.
Methylation switches off drug targets
Promoter methylation causes therapy resistance by chemically modifying the gene that encodes the drug target, stopping that gene from producing the protein the drug binds. The drug does not lose potency. The target disappears. Tumours showing no new mutations on standard sequencing but continuing to progress are frequently carrying this silencing, which standard genetic panels do not detect because the DNA sequence itself is unchanged.
- Methylation pattern divergence – Comparing pre-treatment and post-relapse methylation profiles from the same patient shows silencing patterns that were absent before drug exposure, confirming the tumour developed them under treatment pressure. Extracting those profiles from circulating tumour DNA now makes this detectable from a blood draw, giving oncologists epigenetic resistance data without requiring a second tissue biopsy at relapse.
- Histone compaction blocks transcription – Rising histone deacetylase activity in drug-exposed cells compacts chromatin directly around survival gene clusters, physically blocking transcription machinery from reaching them. Applying deacetylase inhibitors alongside the original targeted agent reopens that chromatin, restores target gene expression, and returns the tumour to a state where the drug can bind its intended protein again.
Repair dependency destroys resistant cells
Tumours that have turned off their primary DNA repair pathway to evade drugs depend entirely on their backup repair mechanism to survive replication. That dependency is the vulnerability. Blocking the backup repair mechanism in that specific tumour causes double-strand DNA breaks to accumulate without resolution, killing the cell through the same deficit it created to resist the original treatment.
Refractory solid tumour cohorts carrying homologous recombination deficiency and treated on this principle show objective responses in patient populations where every prior targeted agent produced zero measurable regression. Response duration in these cohorts extends beyond twelve months in cancers that had progressed through three or more prior lines, and secondary resistance timelines are longer than those recorded with standard single pathway targeted therapy in the same tumour types, indicating the repair collapse mechanism is harder for the cell to work around than conventional drug targets.
New clinical findings convert therapy-proof from a permanent classification into a solvable biological problem. Sequencing identifies the active escape circuit, methylation profiling catches silenced targets standard panels miss, and repair dependency gives resistant cells a vulnerability created by their own survival strategy, each finding connecting directly to a treatment decision rather than a general observation about cancer biology.
